TI-RADS and the Problem of Finding Thyroid Cancers That Never Needed Finding

The Thyroid Imaging Reporting and Data System (TI-RADS) published by the American College of Radiology in 2017 was built to answer one narrow question: which thyroid nodules seen on ultrasound actually warrant a needle biopsy. It scores five sonographic features, adds up the points, and pairs the resulting risk level with a size threshold so that many benign-appearing nodules are watched rather than sampled. The published evidence shows it does reduce unnecessary biopsies. What a scoring system cannot do, though, is undo the deeper problem that sensitive imaging created, which is a steady flow of small thyroid cancers that would never have caused harm.

Why radiologists needed a common language

Thyroid nodules are one of the most common findings in all of medicine. High-resolution ultrasound detects them in a large share of adults, and the overwhelming majority are benign. Before standardized reporting, two radiologists could look at the same nodule and disagree on whether it needed a fine-needle aspiration (FNA). TI-RADS borrowed the logic of BI-RADS in breast imaging: convert a subjective impression into a reproducible score that connects directly to a management recommendation. The ACR committee, led by Franklin Tessler and colleagues, published the white paper in the Journal of the American College of Radiology in 2017.

The five features and the size gate

TI-RADS assigns points across five categories: composition, echogenicity, shape, margin, and echogenic foci. Each feature adds points according to how suspicious it looks, and the running total places a nodule from TR1 (benign) to TR5 (highly suspicious, seven points or more, with TR4 covering four to six). The step that matters most for overdiagnosis is that the recommendation to biopsy depends on both the level and the size. FNA is suggested for a TR5 nodule at one centimeter or larger, a TR4 nodule at 1.5 centimeters, and a TR3 nodule at 2.5 centimeters, with lower thresholds triggering surveillance instead. Below those cutoffs, even a suspicious nodule is followed rather than sampled.

That size gate is a quiet philosophical choice. It builds an explicit tolerance for small cancers into the system, on the reasoning that a tiny suspicious nodule is more safely watched than chased.

The overdiagnosis the system sits inside

Overdiagnosis is not a misdiagnosis. It means correctly identifying a real cancer that would never have produced symptoms or shortened a life. Thyroid cancer is the textbook example. In a widely cited New England Journal of Medicine analysis, Ahn, Kim, and Welch reported that thyroid-cancer diagnoses in South Korea in 2011 ran about fifteen times the 1993 rate as thyroid ultrasound screening spread widely, while thyroid-cancer mortality stayed essentially flat. Incidence climbing steeply while deaths hold steady is the classic fingerprint of overdiagnosis: the extra cancers being found were not the ones that kill.

The consequences are real. A patient given this diagnosis may undergo thyroid surgery, lifelong hormone replacement, and the risks that come with an operation on the neck, all for a tumor that would have stayed silent. Autopsy series have long found occult papillary thyroid cancers in people who died of unrelated causes, evidence of a large reservoir of disease that never declares itself. Long-running active-surveillance programs, most notably at Kuma Hospital in Japan, have shown that most low-risk papillary microcarcinomas grow slowly or not at all over a decade, and that watching them rather than operating is a defensible strategy in selected patients.

Public-health bodies have drawn the obvious conclusion. In 2017 the US Preventive Services Task Force, after a systematic review of the screening evidence, issued a grade D recommendation against screening for thyroid cancer in asymptomatic adults, concluding with moderate certainty that the harms of finding and treating these tumors outweigh the benefits.

What TI-RADS can fix, and what it cannot

Measured against its own goal, TI-RADS performs. The 2021 AJR update by Hoang and colleagues reports that ACR TI-RADS carries higher specificity than competing risk-stratification systems and cuts unnecessary biopsies of benign nodules by roughly a fifth to a half depending on the comparator. Fewer patients endure a needle in the neck for a nodule that was never going to matter.

The limits are structural. TI-RADS operates downstream of detection. It triages nodules that have already been found, and it does nothing to stop the ultrasound, carotid study, or chest CT that surfaces an incidental nodule in the first place. Its specificity gain also comes with a sensitivity trade-off: the system will label some genuine cancers as low risk. When those cancers are the indolent microcarcinomas the reservoir is full of, that is arguably the point rather than a flaw, but it depends on the tumors sorted this way behaving as expected. Feature scoring still varies between readers, and the update is candid that interobserver agreement and validation across populations remain open challenges.

How to read a TI-RADS number

A TR level is a probability estimate attached to a management suggestion, not a verdict. A high number is not a diagnosis of cancer, and a biopsy deferred because a nodule sits below its size threshold is not neglect. It reflects a deliberate judgment, backed by mortality data, that small papillary cancers usually behave indolently and that active surveillance is an evidence-based option worth discussing. The number is most useful when it prompts a conversation about whether finding and acting on a particular nodule is likely to help the patient.

This article is educational and is not medical advice; decisions about a specific nodule belong to a patient and their own clinicians.